These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

285 related items for PubMed ID: 15925069

  • 21. Contemporary survival results and the role of radiation therapy in patients with node negative seminal vesicle invasion following radical prostatectomy.
    Eggener SE, Roehl KA, Smith ND, Antenor JA, Han M, Catalona WJ.
    J Urol; 2005 Apr; 173(4):1150-5. PubMed ID: 15758725
    [Abstract] [Full Text] [Related]

  • 22. Clinical and pathologic outcome after radical prostatectomy for prostate cancer patients with a preoperative Gleason sum of 8 to 10.
    Bastian PJ, Gonzalgo ML, Aronson WJ, Terris MK, Kane CJ, Amling CL, Presti JC, Mangold LA, Humphreys E, Epstein JI, Partin AW, Freedland SJ.
    Cancer; 2006 Sep 15; 107(6):1265-72. PubMed ID: 16900523
    [Abstract] [Full Text] [Related]

  • 23. The extent of lymphadenectomy for pTXNO prostate cancer does not affect prostate cancer outcome in the prostate specific antigen era.
    DiMarco DS, Zincke H, Sebo TJ, Slezak J, Bergstralh EJ, Blute ML.
    J Urol; 2005 Apr 15; 173(4):1121-5. PubMed ID: 15758719
    [Abstract] [Full Text] [Related]

  • 24. Preoperative serum testosterone level as an independent predictor of treatment failure following radical prostatectomy.
    Yamamoto S, Yonese J, Kawakami S, Ohkubo Y, Tatokoro M, Komai Y, Takeshita H, Ishikawa Y, Fukui I.
    Eur Urol; 2007 Sep 15; 52(3):696-701. PubMed ID: 17412490
    [Abstract] [Full Text] [Related]

  • 25. Year of treatment as independent predictor of relapse-free survival in patients with localized prostate cancer treated with definitive radiotherapy in the PSA era.
    Kupelian P, Thames H, Levy L, Horwitz E, Martinez A, Michalski J, Pisansky T, Sandler H, Shipley W, Zelefsky M, Zietman A, Kuban D.
    Int J Radiat Oncol Biol Phys; 2005 Nov 01; 63(3):795-9. PubMed ID: 15925452
    [Abstract] [Full Text] [Related]

  • 26. Visual estimation of tumour extent is not an independent predictor of prostate specific antigen recurrence.
    Jones TD, Koch MO, Lin H, Cheng L.
    BJU Int; 2005 Dec 01; 96(9):1253-7. PubMed ID: 16287440
    [Abstract] [Full Text] [Related]

  • 27. Percentage of positive biopsy cores, preoperative prostate-specific antigen (PSA) level, pT and Gleason score as predictors of PSA recurrence after radical prostatectomy: a multi-institutional outcome study in Japan.
    Yokomizo A, Murai M, Baba S, Ogawa O, Tsukamoto T, Niwakawa M, Tobisu K, Kinukawa N, Naito S.
    BJU Int; 2006 Sep 01; 98(3):549-53. PubMed ID: 16925752
    [Abstract] [Full Text] [Related]

  • 28. Radical prostatectomy for clinically advanced (cT3) prostate cancer since the advent of prostate-specific antigen testing: 15-year outcome.
    Ward JF, Slezak JM, Blute ML, Bergstralh EJ, Zincke H.
    BJU Int; 2005 Apr 01; 95(6):751-6. PubMed ID: 15794776
    [Abstract] [Full Text] [Related]

  • 29. The outcome of patients with pathological Gleason score >or=8 prostate cancer after radical prostatectomy.
    Rodriguez-Covarrubias F, Larre S, De La Taille A, Abbou CC, Salomon L.
    BJU Int; 2008 Feb 01; 101(3):305-7. PubMed ID: 17941921
    [Abstract] [Full Text] [Related]

  • 30. Radical prostatectomy for clinically localized, high risk prostate cancer: critical analysis of risk assessment methods.
    Yossepowitch O, Eggener SE, Bianco FJ, Carver BS, Serio A, Scardino PT, Eastham JA.
    J Urol; 2007 Aug 01; 178(2):493-9; discussion 499. PubMed ID: 17561152
    [Abstract] [Full Text] [Related]

  • 31. Radical prostatectomy for incidental (stage T1a-T1b) prostate cancer: analysis of predictors for residual disease and biochemical recurrence.
    Capitanio U, Scattoni V, Freschi M, Briganti A, Salonia A, Gallina A, Colombo R, Karakiewicz PI, Rigatti P, Montorsi F.
    Eur Urol; 2008 Jul 01; 54(1):118-25. PubMed ID: 18314255
    [Abstract] [Full Text] [Related]

  • 32. Long-term outcome following radical prostatectomy in men with clinical stage T3 prostate cancer.
    Carver BS, Bianco FJ, Scardino PT, Eastham JA.
    J Urol; 2006 Aug 01; 176(2):564-8. PubMed ID: 16813890
    [Abstract] [Full Text] [Related]

  • 33. Expression of biomarkers modulating prostate cancer progression: implications in the treatment of the disease.
    Di Lorenzo G, De Placido S, Autorino R, De Laurentiis M, Mignogna C, D'Armiento M, Tortora G, De Rosa G, D'Armiento M, De Sio M, Bianco AR, D'Armiento FP.
    Prostate Cancer Prostatic Dis; 2005 Aug 01; 8(1):54-9. PubMed ID: 15655565
    [Abstract] [Full Text] [Related]

  • 34. Tumour volume is an independent predictor of prostate-specific antigen recurrence in patients undergoing radical prostatectomy for clinically localized prostate cancer.
    Nelson BA, Shappell SB, Chang SS, Wells N, Farnham SB, Smith JA, Cookson MS.
    BJU Int; 2006 Jun 01; 97(6):1169-72. PubMed ID: 16686706
    [Abstract] [Full Text] [Related]

  • 35. Delay in surgical therapy for clinically localized prostate cancer and biochemical recurrence after radical prostatectomy.
    Nam RK, Jewett MA, Krahn MD, Robinette MA, Tsihlias J, Toi A, Ho M, Evans A, Sweet J, Trachtenberg J.
    Can J Urol; 2003 Jun 01; 10(3):1891-8. PubMed ID: 12892576
    [Abstract] [Full Text] [Related]

  • 36. Prognostic indicators for long term outcome following radical retropubic prostatectomy for prostate cancer involving the seminal vesicles.
    Johnson CW, Anastasiadis AG, McKiernan JM, Salomon L, Eaton S, Goluboff ET, Olsson CA, Benson MC.
    Urol Oncol; 2004 Jun 01; 22(2):107-11. PubMed ID: 15082006
    [Abstract] [Full Text] [Related]

  • 37. Prostate-specific antigen doubling time predicts clinical outcome and survival in prostate cancer patients treated with combined radiation and hormone therapy.
    Lee AK, Levy LB, Cheung R, Kuban D.
    Int J Radiat Oncol Biol Phys; 2005 Oct 01; 63(2):456-62. PubMed ID: 15927415
    [Abstract] [Full Text] [Related]

  • 38. Impact of patient age on biochemical recurrence rates following radical prostatectomy.
    Magheli A, Rais-Bahrami S, Humphreys EB, Peck HJ, Trock BJ, Gonzalgo ML.
    J Urol; 2007 Nov 01; 178(5):1933-7; discussion 1937-8. PubMed ID: 17868723
    [Abstract] [Full Text] [Related]

  • 39. Predictors of prostate cancer-specific mortality after radical prostatectomy or radiation therapy.
    Zhou P, Chen MH, McLeod D, Carroll PR, Moul JW, D'Amico AV.
    J Clin Oncol; 2005 Oct 01; 23(28):6992-8. PubMed ID: 16192586
    [Abstract] [Full Text] [Related]

  • 40. Effect of delaying surgery on radical prostatectomy outcomes: a contemporary analysis.
    Korets R, Seager CM, Pitman MS, Hruby GW, Benson MC, McKiernan JM.
    BJU Int; 2012 Jul 01; 110(2):211-6. PubMed ID: 22093486
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 15.